Xencor Inc cash flow statement
In fiscal 2025, Xencor Inc's operations generated −$135m of cash; it spent $3.1m on capital projects, leaving free cash flow of −$138m.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 95 | −34 | −80 | 64 | −5 | −17 | 24 | −78 | −202 | −135 | −206 |
| Depreciation and amortisation | 1 | 2 | 3 | 4 | 6 | 7 | 9 | 11 | 12 | 11 | 10 |
| Stock-based pay | 8 | 14 | 21 | 32 | 32 | 37 | 49 | 54 | 53 | 43 | 39 |
| Capital spending | 2 | 5 | 7 | 7 | 11 | 13 | 38 | 18 | 6 | 3 | 2 |
| Free cash flow | 94 | −39 | −87 | 57 | −16 | −30 | −14 | −96 | −208 | −138 | −208 |
| Free cash flow after stock pay | 86 | −53 | −108 | 25 | −47 | −67 | −63 | −150 | −262 | −181 | −247 |
| Shares issued | 127 | — | 260 | — | 0 | 29 | 0 | 0 | 201 | 0 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −28 | −50 | −16 | −36 | −31 | −52 | −68 | −56 |
| Depreciation and amortisation | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 2 |
| Stock-based pay | 12 | 12 | 12 | 11 | 10 | 10 | 10 | 9 |
| Capital spending | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Free cash flow | −29 | −52 | −18 | −37 | −31 | −53 | −68 | −56 |
| Free cash flow after stock pay | −42 | −64 | −30 | −47 | −41 | −63 | −78 | −65 |
| Shares issued | — | 0 | — | — | — | 0 | — | — |
Compare with peers
- Kymera Therapeutics, Inc. cash flow
- Septerna, Inc. cash flow
- Agios Pharmaceuticals, Inc. cash flow
- ARS Pharmaceuticals, Inc. cash flow
- Arcus Biosciences, Inc. cash flow
Head to head: KYMR vs XNCRSEPN vs XNCRAGIO vs XNCRSPRY vs XNCR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies